Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

NAMS Position Statement on Hormone Therapy Updated

Menopause; ePub 2017 Jun 20; Pinkerton, et al

The North American Menopause Society (NAMS) has issued its updated 2017 position statement that contains guidelines for hormone therapy use. The statement includes updated information and new findings since the last issue in 2012. Among the conclusions and new or expanded areas covered in the statement:

  • Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause.
  • The risks of HT differ for different women and treatment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation for the benefits and risk of HT continuation.
  • For women aged <60 years or who are within 10 years of menopause onset, the benefit-risk ratio appears favorable for HT treatment.
  • The risk of heart disease is greater in women who start HT >10 years after menopause onset or after age 60 years.
  • Vaginal estrogen or other nonestrogen therapies may be used at any age for prevention or treatment of the genitourinary syndrome or menopause.


Pinkerton JV, for the NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. [Published online ahead of print June 20, 2017]. Menopause. doi:10.1097/GME.0000000000000921.